Cita APA (7a ed.)
Ikeda, M., Fujimoto, K., Miura, N., Taoka, R., Nishihara, K., Ikarashi, D., . . . Kikuchi, E. (2025). A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS). Current Oncology, 32(11), 618-634.
Cita Chicago Style (17a ed.)
Ikeda, Masaomi, et al. "A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS)." Current Oncology 32, no. 11 (2025): 618-634.
Cita MLA (9a ed.)
Ikeda, Masaomi, et al. "A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS)." Current Oncology, vol. 32, no. 11, 2025, pp. 618-634.
Precaución: Estas citas no son 100% exactas.